Pfizer Inc. announced it will present data from over 100 company-sponsored, investigator-sponsored, and collaborative research abstracts at the American Society of Hematology (ASH) Annual Meeting & Exposition and the San Antonio Breast Cancer Symposium (SABCS). These presentations will highlight advancements across its growing hematology and breast cancer portfolios.
Key presentations at ASH include updated analyses from the pivotal ECHELON-3 trial for ADCETRIS in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), and new data for ELREXFIO in relapsed/refractory multiple myeloma (RRMM). Pfizer will also share Phase 1 combination data for SEA-CD70 in high-risk myelodysplastic syndromes, showcasing its next-generation pipeline.
At SABCS, Pfizer will present 30 abstracts, including real-world analyses affirming IBRANCE as a first-line standard-of-care for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). New and updated Phase 1 data for pipeline candidates like atirmociclib, vepdegestrant, and the novel KAT6 inhibitor, PF-07248144, will also be featured, demonstrating Pfizer's commitment to innovative therapies in breast cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.